Tag: NSCLC,Non-Small Cell Lung Cancer,Press Releases,Series E Financing,Veristrat,blood-based cancer test,cancer diagnostics,liquid biopsy,serum protein test

Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company increased the size of its recent offering of series E preferred shares in a follow-on sale. In addition to the $8.3 million of series E shares sold a month ago, the company brought in another $6.1 million, for…